Literature DB >> 6144492

pH-dependent rearrangement of the biosynthetic ester glucuronide of valproic acid to beta-glucuronidase-resistant forms.

R G Dickinson, W D Hooper, M J Eadie.   

Abstract

A major metabolite of the antiepileptic drug valproic acid (VPA) in animals and man is the glucuronic acid conjugate, which is cleaved by incubation with beta-glucuronidase (specific for 1-O-substituted-beta-D-glucopyranosiduronic acids) or hydrolysis in strong acid or alkali. Previous studies revealed that an often substantial proportion of the alkali-labile conjugated VPA in stored urine or bile samples was not hydrolyzed by beta-glucuronidase, suggesting the presence of nonglucuronide conjugates. In the present study, bile from a NaVPA-treated rat was preincubated at 37 degrees C for 3 hr at pH values from -0.8 to 12.9, and then analyzed for nonconjugated VPA, VPA released by hydrolysis with beta-glucuronidase, and VPA released by hydrolysis with alkali. At pH 3-7, all alkali-labile conjugated VPA remained susceptible to beta-glucuronidase hydrolysis, whereas at pH 0-3 and 7-11, a proportion became resistant to the enzyme. GLC and GC/MS analysis of trimethylsilyl derivatives of the intact conjugates revealed the appearance of seven additional peaks, adjacent to the biosynthetic ester glucuronide, of which six were structural isomers and one was a dehydrated species. The data were consistent with acid- and base-catalyzed intramolecular acyl migration of the valproate moiety away from the C-1 position, with subsequent processes of ring-opening, mutarotation, and lactonization yielding structural isomers and lactones which were not substrates for beta-glucuronidase. It was further shown that these rearrangements are time- and temperature-dependent. Consequently, sample handling and storage conditions of ester glucuronides prior to analysis are of prime importance, since hydrolysis with beta-glucuronidase is frequently used for identification and quantification of glucuronides.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144492

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-09       Impact factor: 2.745

2.  Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.

Authors:  M Shipkova; V W Armstrong; E Wieland; P D Niedmann; E Schütz; G Brenner-Weiss; M Voihsel; F Braun; M Oellerich
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

3.  Direct measurement of probenecid and its glucuronide conjugate by means of high pressure liquid chromatography in plasma and urine of humans.

Authors:  T B Vree; E W Beneken Kolmer
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

4.  Self-micellization of gemfibrozil 1-O-beta acyl glucuronide in aqueous solution.

Authors:  David M Shackleford; Richard J Prankerd; Martin J Scanlon; William N Charman
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

5.  Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles.

Authors:  Yong Ma; Song Gao; Ming Hu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-07-19       Impact factor: 3.205

Review 6.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

7.  Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans.

Authors:  T B Vree; E W Van Ewijk-Beneken Kolmer; E W Wuis; Y A Hekster; M M Broekman
Journal:  Pharm World Sci       Date:  1993-10-15

Review 8.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

9.  Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study.

Authors:  T B Vree; E W Van Ewijk-Beneken Kolmer; E W Wuis; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1992-10-16

10.  Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10.

Authors:  Upendra A Argikar; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2008-10-06       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.